argenx Announces VYVGART (efgartigimod alfa) Authorized for

21.09.2023 - VYVGARTⓇ is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p

Related Keywords

Toronto , Ontario , Canada , Amsterdam , Noord Holland , Netherlands , Stacey Lintern , Division Of Neurology , University Health Network , Health Canada , University Of Toronto , Vera Bril , Neuromuscular Section , University Health , Chief Executive Officer , Muscular Dystrophy , Quantitative Myasthenia Gravis , Argenx Aktie ,